Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy

Molecular Cancer Therapeutics

Volumn 5, Issue 3, 2006, Pages 693-703

  Caldas, Hugo ^a   Jaynes, Florinda O ^a   Boyer, Michael W ^a   Hammond, Sue ^a,b   Altura, Rachel A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GRANZYME B; PACLITAXEL; PLASMID DNA; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; FUSION GENE; GENE SEQUENCE; GENE VECTOR; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TOXICITY TESTING; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; ARTIFICIAL GENE FUSION; CARCINOMA; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; GRANZYMES; HUMANS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; PROMOTER REGIONS (GENETICS); SERINE ENDOPEPTIDASES; TRANSFECTION;

EID: 33645465144     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0423     Document Type: Article

References (46)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Leung EH, Leung PC, Auersperg N. Differentiation and growth potential of human ovarian surface epithelial cells expressing temperature-sensitive SV40 T antigen. In vitro Cell Dev Biol Anim 2001;37:515-21.
3. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002;21:315-20.
4. Ferrandina G, Legge F, Martinelli E, et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 2005;92:271-7.
5. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B. A natural born killer. Immunol Rev 2003;193:31-8.
6. Trapani JA, Sutton VR. Granzyme B. pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol 2003;15:533-43.
7. Adrain C, Murphy BM, Martin SJ. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease Granzyme B. J Biol Chem 2005;280:4663-73.
8. Metkar SS, Wang B, Ebbs ML, et al. Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J Cell Biol 2003;160:875-85.
9. Talanian RV, Yang X, Turbov J, et al. Granule-mediated killing: pathways for Granzyme B-initiated apoptosis. J Exp Med 1997;186: 1323-31.
10. Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breard J. Direct cleavage of ROCK II by Granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med 2005;201:465-71.
11. Bao R, Connolly DC, Murphy M, et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002;94: 522-8.
12. Chen JS, Liu JC, Shen L, et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004;11:740-7.
13. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
14. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005; 24:1994-2007.
15. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005;4:11.
16. Fangusaro JR, Jiang Y, Holloway MP, et al. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005;92: 359-65.
17. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004; 279:40511-20.
18. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344Pt 2:305-11.
19. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-57.
20. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-22.
21. Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.
22. Tait L, Soule HD, Russo J. Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6087-94.
23. Zhu ZB, Makhija SK, Lu B, et al. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther 2004; 11:256-62.
24. Morimoto H, Safrit JT, Bonavida B. Synergistic effect of tumor necrosis factor-alpha-and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol 1991;147: 2609-16.
25. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
26. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
27. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-16.
28. Caisey JD, King DJ. Clinical chemical values for some common laboratory animals. Clin Chem 1980;26:1877-9.
29. Wolford ST, Schroer RA, Gohs FX, et al. Reference range data base for serum chemistry and hematology values in laboratory animals. J Toxicol Environ Health 1986;18:161-88.
30. Loeb WF, Das SR, Harbour LS, Turturro A, Bucci TJ, Clifford CB. Clinical biochemistry. In: Mohr U, Dungworth DL, Capen CC, Carlton WW, Sundberg JP, Ward JM, editors. Pathobiology of the aging mouse. Washington (District of Columbia): ILSI Press; 1996. p. 3-19.
31. Levine BS. Animal clinical pathology. In: Derelanko MJ, Hollinger MA, editors. CRC handbook of toxicology. Boca Raton (FL): CRC Press; 1995. p. 517-37.
32. Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Semin Oncol 2000; 27:8-10.
33. Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology (Huntingt) 1997;11:95-105.
34. Ikeda H, Chamoto K, Tsuji T, et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004;95: 697-703.
35. Ottaiano A, Mollo E, Di Lorenzo G, et al. Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. Cancer Immunol Immunother 2005;54:44-50.
36. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004;64: 9160-6.
37. Smith CL, Dunbar PR, Mirza F, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005;113:259-66.
38. Vassaux G, Martin-Duque P. Use of suicide genes for cancer gene therapy: study of the different approaches. Expert Opin Biol Ther 2004; 4:519-30.
39. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002;8: S68-73.
40. Barry M, Heibein JA, Pinkoski MJ, et al. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol 2000;20: 3781-94.
41. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90.
42. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999;144:281-92.
43. Sutton VR, Wowk ME, Cancilla M, Trapani JA. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 2003;18:319-29.
44. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
45. De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci U S A 1981;78:5608-12.
46. 2-M arrest. J Biol Chem 2004;279:15196-203.